🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Examining patient and professional perspectives in the UK for gene therapy in #haemophilia #PREFERlegacy 👇 onlinelibrary.wiley.com/doi/10.1111/ha…

How do public-private partnerships help early career researchers (ECRs) get ahead professionally? Find out from ECRs from IMI projects PREFER: patient preferences EHDEN imisophia EU-PEARL Project at our online event! 🗓️ 17.04.23 📍 Online ➡️ Info + registration: bit.ly/3lYygzI

⏰Our #ImpactSeriesIMI event on IMI's impact on early career researchers is in 2 weeks! Meet Eline van Overbeeke of PREFER: patient preferences EHDEN, Pierre Bauvin of imisophia & Elias Meyer of EU-PEARL Project & find out how working in IMI projects helped their career ➡️ bit.ly/3lYygzI

Acceptable risks of treatments to prevent #rheumatoidarthritis among first-degree relatives: demographic and psychological predictors of risk tolerance 👇 rmdopen.bmj.com/content/8/2/e0…

Preferences for preventive treatments for #rheumatoidarthritis: discrete choice survey in the UK, Germany and Romania 👇 doi.org/10.1093/rheuma…

JUST PUBLISHED: Patients as research partners in preference studies: learnings from IMI-PREFER 👇researchinvolvement.biomedcentral.com/articles/10.11…

Involving patient research partners in preference studies requires dedicated resources and expertise, but it's worth it! New paper from PREFER: patient preferences rdcu.be/c9Qd6 Birmingham Rheumatology Research Group @NIHRBhamBRC R2P2 @unibirm_MDS Inflammation and Ageing

Our webinar on IMI's impact on early career researchers is on Monday! This will be a great event featuring some inspiring young scientists. Not signed up yet? Go to bit.ly/3lYygzI

.Eline van Overbeeke played a key role in the PREFER: patient preferences project's PAVING study which explored what matters to Belgian haemophilia patients #ResearchImpactIMI

17 papers published, 12 presentations at congresses and multiple interactions with diverse stakeholders... Eline van Overbeeke summarises the outcomes for her personally from participating in IMI projects.

Our #ImpactSeriesIMI speakers outline the benefits for early career researchers of joining a PPP project ... - Good overview of the kinds of jobs available (and job opportunities) - Great opportunity to build your network with high-level people from diverse organisations

Take-home messages from the PREFER Recommendations, explaining when and why structured input from patient preference studies can support decision making. 👇 youtu.be/xqJiAUC4eSg

Missed our #ImpactSeriesIMI event yesterday on early career researchers? Catch up online: youtu.be/WqPIX_wnjYY Eline van Overbeeke Pierre Bauvin PREFER: patient preferences imisophia EHDEN EU-PEARL Project

Why, when and how to assess and use patient preferences in medical product decision-making. The PREFER Recommendations zenodo.org/record/6592304

We received a positive qualification opinion on the PREFER framework and points to consider for method selection for a patient preference study from EU Medicines Agency. Want to know more about the process? 👇 youtu.be/KqQG9IFh8r4

Want to know why, when and how PREFER recommends that pharma, regulators, HTA bodies and payers assess and use patient preferences in medical product decision-making? zenodo.org/record/6470918…

We have shared our reports and templates #OpenAccess. Want to use them? Take a look at the PREFER Zenodo community! zenodo.org/communities/pr… x.com/ZENODO_ORG/sta…

People affected with bacterial infections can & should be involved in every step of antibiotic #DrugDevelopment🗨️ Read through take-home recommendations from our last #SciComm Interest Group Meeting on how to leverage #CommunityEngagement in #AMR research: amr-accelerator.eu/allgemein/scie…

Comparing Outcomes of a Discrete Choice Experiment and Case 2 Best-Worst Scaling: An Application to Neuromuscular Disease Treatment 👇 link.springer.com/article/10.100…

Rebecca Noel, Global Leader for Benefit-Risk Assessment Eli Lilly and Company & member of PREFER: patient preferences speaks to the value of patient preference information, which can be used across the lifecycle of drug development ➡tinyurl.com/NO-PED-without…. #patientengagement #patientexperiencedata